Yi Lin

38.5k total citations · 4 hit papers
299 papers, 9.1k citations indexed

About

Yi Lin is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Yi Lin has authored 299 papers receiving a total of 9.1k indexed citations (citations by other indexed papers that have themselves been cited), including 159 papers in Oncology, 74 papers in Molecular Biology and 65 papers in Hematology. Recurrent topics in Yi Lin's work include CAR-T cell therapy research (134 papers), Multiple Myeloma Research and Treatments (56 papers) and Lymphoma Diagnosis and Treatment (33 papers). Yi Lin is often cited by papers focused on CAR-T cell therapy research (134 papers), Multiple Myeloma Research and Treatments (56 papers) and Lymphoma Diagnosis and Treatment (33 papers). Yi Lin collaborates with scholars based in United States, China and France. Yi Lin's co-authors include Anna Solovey, Robert P. Hebbel, Daniel J. Weisdorf, Allan B. Dietz, Sattva S. Neelapu, Frederick L. Locke, Michael P. Gustafson, Peggy A. Bulur, William G. Wierda and Partow Kebriaei and has published in prestigious journals such as New England Journal of Medicine, Journal of the American Chemical Society and Journal of Biological Chemistry.

In The Last Decade

Yi Lin

274 papers receiving 8.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

2017 1.6k citations Frederick L. Locke, Yi Lin et al. profile →
Origins of circulating endothelial cells and endothelial outgrowth from blood

2000 1.2k citations Yi Lin et al. profile →
Circulating Activated Endothelial Cells in Sickle Cell Anemia

1997 509 citations Yi Lin et al. profile →
Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial

2022 186 citations Javier Muñoz, Yi Lin et al. profile →

Peers

Countries citing papers authored by Yi Lin

Since Specialization

Citations

This map shows the geographic impact of Yi Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yi Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yi Lin more than expected).

Fields of papers citing papers by Yi Lin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yi Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yi Lin. The network helps show where Yi Lin may publish in the future.

Co-authorship network of co-authors of Yi Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Yi Lin. A scholar is included among the top collaborators of Yi Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yi Lin. Yi Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Effectiveness and Safety Outcomes of Standard of Care (SOC) Lisocabtagene Maraleucel (liso-cel) in Patients (Pts) with Relapsed or Refractory (R/R) Transformed Large B-Cell Lymphoma (tLBCL): Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry 2025 ·Transplantation and Cellular Therapy ·Iris Isufi, Jennifer L. Crombie, Matthew J. Frigault, Charalambos Andreadis, Yi Lin, Abu‐Sayeef Mirza, Soyoung Kim, (unknown), (unknown), (unknown), Debasmita Roy, Marcelo C. Pasquini, Sairah Ahmed	0
2	The ratio of brain to liver glucose activity and disease activity in multiple myeloma 2025 ·Blood Cancer Journal ·(unknown), (unknown), Moritz Binder, Joselle Cook, Morie A. Gertz, Suzanne R. Hayman, Prashant Kapoor, Taxiarchis Kourelis, Shaji Kumar, Mustaqeem Siddiqui, Rahma Warsame, Yi Lin, Arthur G. Erdman, David Dingli	0
3	Impact of IVF-ET on obstetrics and perinatal outcomes in advanced maternal age women 2025 ·Placenta ·Qian Li, Xiaowei Wei, Weihong Zeng, Yi Lin	0
4	Baseline echocardiographic variables as predictors of hemodynamically significant cytokine release syndrome in adults treated with CD19 CAR T-cell therapy for hematological malignancies 2024 ·Cardio-Oncology ·(unknown), Muhannad Abbasi, (unknown), (unknown), (unknown), Yi Lin, Jonas Paludo, Joerg Herrmann, Stephen M. Ansell, Allison Rosenthal, Hector R. Villarraga	2
5	Low magnesium levels and prognosis in newly diagnosed diffuse large B-cell lymphoma 2024 ·The Oncologist ·Jennifer Gile, Matthew J. Maurer, Gordon Ruan, Jithma P. Abeykoon, (unknown), N Baumann, Molly McMahon, Yi Lin, Thomas E. Witzig	0
6	Comprehensive profiling of cancer neoantigens from aberrant RNA splicing 2024 ·Journal for ImmunoTherapy of Cancer ·Daniel P. Wickland, (unknown), Erik Jessen, Brian M. Necela, (unknown), Yi Lin, Keith L. Knutson, Yan W. Asmann	4
7	Mode of progression in smoldering multiple myeloma: a study of 406 patients 2024 ·Blood Cancer Journal ·Nadine Abdallah, Arjun Lakshman, Shaji Kumar, Joselle Cook, Moritz Binder, Prashant Kapoor, Angela Dispenzieri, Morie A. Gertz, Martha Q. Lacy, Suzanne R. Hayman, Francis K. Buadi, David Dingli, Yi Lin, Taxiarchis Kourelis, Rahma Warsame, Leif Bergsagel, S. Vincent Rajkumar	10
8	Incorporating radiation with anti‐CD19 chimeric antigen receptor T‐cell therapy for relapsed/refractory non‐Hodgkin lymphoma: A multicenter consensus approach 2023 ·American Journal of Hematology ·Omran Saifi, Scott C. Lester, William G. Breen, William G. Rule, Yi Lin, N. Nora Bennani, Allison Rosenthal, Javier Muñoz, Hemant S. Murthy, Mohamed A. Kharfan‐Dabaja, Jennifer Peterson, Bradford S. Hoppe	9
9	Adverse obstetric and perinatal outcomes of patients with history of recurrent miscarriage: a retrospective cohort study 2023 ·Fertility and Sterility ·Jinwen Zhang, Xiaorui Liu, Lin Rao, Ruixiang Ma, (unknown), Cailian Chen, Yi Lin	8
10	Applying the Novel EHA/EBMT Grading System for Icaht Following CAR-T Therapy: Comparative Incidence across Disease Entities and Association with Infections and Mortality 2023 ·Blood ·Kai Rejeski, Doris K. Hansen, Yucai Wang, Gloria Iacoboni, Emmanuel Bachy, Radhika Bansal, Olaf Penack, (unknown), Wolfgang Bethge, Javier Muñoz, Razan Mohty, Veit Buecklein, Pere Barba, Frederick L. Locke, Yi Lin, Michael D. Jain, Marion Subklewe	1
11	The CAR‐HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL 2023 ·American Journal of Hematology ·Kai Rejeski, Yucai Wang, Omar Albanyan, Javier Muñoz, Pierre Sesques, Gloria Iacoboni, Lucía López‐Corral, (unknown), Veit Bücklein, Razan Mohty, Martin Dreyling, Aliyah Baluch, Bijal Shah, Frederick L. Locke, Georg Heß, Pere Barba, Emmanuel Bachy, Yi Lin, Marion Subklewe, Michael D. Jain	17
12	Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma 2023 ·Blood Cancer Journal ·Radhika Bansal, (unknown), Jeremy T. Larsen, Matthew Hathcock, David Dingli, A. Keith Stewart, Prashant Kapoor, Taxiarchis Kourelis, Suzanne R. Hayman, Rahma Warsame, Rafaël Fonseca, P. Leif Bergsagel, Sikander Ailawadhi, Shaji Kumar, Yi Lin	13
13	Prognostic Value of Early Bone Marrow MRD Status in CAR-T Therapy for Myeloma 2022 ·Transplantation and Cellular Therapy ·Radhika Bansal, (unknown), Jeremy T. Larsen, Matthew Hathcock, David Dingli, Keith Stewart, Prashant Kapoor, Taxiarchis Kourelis, Suzanne R. Hayman, Rahma Warsame, Rafaël Fonseca, P. Leif Bergsagel, Sikander Ailawadhi, Shaji Kumar, Yi Lin	2
14	LncRNA OR2A1‐AS1 index predicts survival in germinal center‐like diffuse large B‐cell lymphoma 2022 ·Journal of Clinical Laboratory Analysis ·Shuting Ye, (unknown), Yi Lin, (unknown), (unknown)	5
15	Impact of Rituximab and Corticosteroids on Late Cytopenias Post-Chimeric Antigen Receptor T Cell Therapy 2022 ·Transplantation and Cellular Therapy ·Madiha Iqbal, Radhika Bansal, (unknown), (unknown), Allison Rosenthal, Muhamad Alhaj Moustafa, Zhuo Li, (unknown), Razan Mohty, Hemant S. Murthy, Ernesto Ayala, Han W. Tun, Javier Muñoz, Januario E. Castro, Yi Lin, Mohamed A. Kharfan‐Dabaja	5
16	Lines of Therapy before Autologous Stem Cell Transplant (ASCT) and CAR-T Infusion Affect Outcomes in Aggressive Non-Hodgkin’s Lymphoma (NHL) 2021 ·Transplantation and Cellular Therapy ·Arushi Khurana, Matthew Hathcock, Thomas M. Habermann, Abdullah S. Al Saleh, (unknown), Tuan Truong, N. Nora Bennani, Jonas Paludo, José C. Villasboas, (unknown), David J. Inwards, Luis F. Porrata, Patrick B. Johnston, Ivana N. Micallef, Yi Lin	1
17	Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis 2021 ·Transplantation and Cellular Therapy ·Jesús G. Berdeja, Noopur Raje, David S. Siegel, Yi Lin, Larry D. Anderson, Paula Rodríguez‐Otero, Salomon Manier, Hermann Einsele, Michèle Cavo, Anna Truppel-Hartmann, Everton Rowe, (unknown), Julie Wang, Timothy Campbell, Sundar Jagannath	2
18	Intratumoral CD14+ Cells and Circulating CD14+HLA-DRlo/neg Monocytes Correlate with Decreased Survival in Patients with Clear Cell Renal Cell Carcinoma 2015 ·Clinical Cancer Research ·Michael P. Gustafson, Yi Lin, Jonathan Bleeker, Deepti Warad, Matthew K. Tollefson, Paul L. Crispen, Peggy A. Bulur, Susan M. Harrington, Rebecca R. Laborde, Dennis A. Gastineau, Bradley C. Leibovich, John C. Cheville, Eugene D. Kwon, Allan B. Dietz	38
19	The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation 2015 ·Nephrology Dialysis Transplantation ·Nelson Leung, Shaji Kumar, Siobhán Glavey, Angela Dispenzieri, Martha Q. Lacy, Francis K. Buadi, Suzanne R. Hayman, David Dingli, Prashant Kapoor, Steven R. Zeldenrust, Stephen J. Russell, John A. Lust, William J. Hogan, S. Vincent Rajkumar, Dennis A. Gastineau, Taxiarchis Kourelis, Yi Lin, Wilson I. Gonsalves, Ronald S. Go, Morie A. Gertz	22
20	Importance of Achieving Stringent Complete Response After Autologous Stem-Cell Transplantation in Multiple Myeloma 2013 ·Journal of Clinical Oncology ·Prashant Kapoor, Shaji Kumar, Angela Dispenzieri, Martha Q. Lacy, Francis K. Buadi, David Dingli, Stephen J. Russell, Suzanne R. Hayman, Thomas E. Witzig, John A. Lust, Nelson Leung, Yi Lin, Steven R. Zeldenrust, Arleigh McCurdy, Philip R. Greipp, Robert A. Kyle, S. Vincent Rajkumar, Morie A. Gertz	120

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact